Drug intelligence / Profile preview

Biokine Derma

Development stage: Unknown
Lead developer: Adamas Biotech
Modality: Small Molecules
Administration: Topical

Overview

Biokine Derma is a topical nutraceutical candidate being developed by Adamas Biotech for the treatment of psoriasis. Currently in Phase 1 clinical development, the product is based on green tea catechins, which are known for their anti-inflammatory and antioxidant properties. Biokine Derma is part of the company's Biokine line, which focuses on utilizing natural compounds to modulate cytokine activity and manage inflammatory skin conditions. The treatment is intended to address psoriatic lesions by reducing localized inflammation and oxidative stress through dermal application.

Brand names: Biokine Derma

Beyond the preview

Go deeper on Biokine Derma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biokine Derma.

Explore the full profile